Drugs / Seretide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT02813200 | Jan 2017 → Feb 2019 | chronic obstructive pulmonary disease | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 4 | NCT01647646 | Mar 2009 → Feb 2011 | asthma | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT00642148 Comparator | Feb 2008 → Jul 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03468790 Background | May 2018 → Jan 2021 | allergic asthma | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT03461627 Comparator | Apr 2017 → Oct 2018 | asthma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01274325 Comparator | Feb 2011 → Apr 2013 | asthma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00628758 Background | Dec 2005 → Sep 2008 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00262587 Comparator | Sep 2005 → Dec 2008 | asthma | Bispebjerg Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seretide | “Seretide disc 100-250-500 mcg/dosage 60 dosage” NCT00628758 ↗ |
| Route | Inhaled | “Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)” NCT00262587 ↗ |